导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.17% | 2149/4773 |
| 近一周 | -1.99% | 1030/5462 |
| 近一月 | -3.75% | 1939/5421 |
| 近一季 | -6.36% | 2062/5209 |
| 近半年 | -1.73% | 1677/4920 |
| 近一年 | 2.58% | 2090/4366 |
| 近两年 | 49.47% | 1480/2954 |
| 近三年 | 30.42% | 1040/2253 |
| 成立以来 | 55.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.14% 3054/4961 |
13.18% 2048/5312 |
- - |
- - |
| 2025 | 19.92% 2165/4813 |
-0.77% 2401/3635 |
1.64% 2250/4076 |
18.48% 2298/4524 |
0.36% 2043/4813 |
| 2024 | 15.77% 888/3463 |
2.43% 777/2808 |
-1.46% 1068/3014 |
16.25% 1497/3129 |
-1.34% 1660/3463 |
| 2023 | -9.44% 1163/2656 |
3.71% 1144/2280 |
-4.56% 1201/2385 |
-2.82% 758/2515 |
-5.86% 1531/2655 |
| 2022 | -18.25% 679/2207 |
-14.14% 910/1919 |
7.15% 522/2016 |
-12.39% 702/2113 |
1.44% 1266/2208 |
| 2021 | 4.40% 580/1822 |
-3.13% 765/1255 |
8.85% 604/1330 |
-3.00% 607/1466 |
2.07% 709/1822 |
| 2020 | 34.96% 428/1250 |
-6.19% 467/1028 |
15.51% 491/1067 |
9.57% 640/1164 |
13.68% 339/1184 |
| 2019 | 37.73% 332/1092 |
24.94% 490/739 |
-0.19% 224/788 |
2.60% 294/850 |
7.64% 417/918 |
| 2018 | - - |
- - |
-9.16% 268/631 |
-1.12% 232/660 |
-11.23% 269/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| MSCI中国A股国际通联接C VS. 长安沪深300非周期A(740101) |